Royalty Pharma plc (NASDAQ:RPRX) finished Friday with an addition of $0.65 to close at $30.21, an upside of 2.20 percent. An average of 2,136,060 shares of common stock have been traded in the last five days. There was a gain of $0.87 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 2,055,705 shares traded, while the 50-day average volume stands at 2,259,580.
RPRX stock has decreased by -2.55% in the last month. The company shares reached their 1-month lowest point of $28.98 on 08/18/23. With the stock rallying to its 52-week high on 01/03/23, shares of the company touched a low of $28.98 and a high of $44.47 in 52 weeks. It has reached a new high 1 time so far this year and lost -23.56% or -$9.31 in price. In spite of this, the price is down -32.07% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
RPRX stock investors should be aware that Royalty Pharma plc (RPRX) stock had its last reported insider trading activity 16 days ago on Aug 10. In this transaction, the insider spent $1,153,091. EVP & CFO, Coyne Terrance P., disposed of 37,500 shares at a price of $30.72 on Aug 09. The insider now owns more than $1,151,936 worth of shares. Prior to that, EVP & CFO Coyne Terrance P. went on to Sale 37,500 shares at $30.93 each on Jul 13. An amount of $1,159,958 was transacted.
Valuation Metrics
Royalty Pharma plc (RPRX) has a trailing price-to-earnings (P/E) ratio of 53.75. The stock’s beta is 0.40. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 7.68, the price-to-book (PB) ratio at 2.17, and the price-to-cash flow ratio at 34.77.
The company has a payout ratio of 138.40%. The company’s most recent quarterly dividend payment was $0.20 a share, without any change from last year. Its latest increase dividend $0.01 reported on Monday January 9 2023.
Financial Health
The quick ratio of Royalty Pharma plc for the three months ended June 29 was 2.50, and the current ratio was 2.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.98 and a total debt to equity ratio of 1.13 for the quarter ending June 29. Its gross profit as reported stood at $1.93 billion compared to revenue of $2.24 billion.
Earnings Surprise
For the three-month period that ended June 29, Royalty Pharma plc had $6.13 billion in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $227.63 million in the quarter, while revenues were shrunk -33.77%. The analyst consensus anticipated Royalty Pharma plc’s latest quarter earnings to come in at $0.81 per share, but it turned out to be $0.84, a 3.70% surprise. For the quarter, EBITDA amounted to $254.16 million. Shareholders own equity worth $601.82 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Royalty Pharma plc (RPRX) price momentum. RSI 9-day as of the close on 25 August was 55.03%, suggesting the stock is Neutral, with historical volatility in this time frame at 17.21%.
As of today, RPRX’s price is $29.74 +2.97% or $0.87 from its 5-day moving average. RPRX is currently trading -3.27% lower than its 20-day SMA and -15.80% lower than its 100-day SMA. However, the stock’s current price level is -6.03% below the SMA50 and -28.70% below the SMA200.
The stochastic %K and %D were 34.42% and 29.43%, respectively, and the average true range (ATR) was 0.59. With the 14-day stochastic at 50.51% and the average true range at 0.58, the RSI (14) stands at 48.82%. The stock has reached 0.17 on the 9-day MACD Oscillator while the 14-day reading was at -0.12.
Analyst Ratings
The consensus rating for Royalty Pharma plc (RPRX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell RPRX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 8 others rate it as a “buy”.
What is RPRX’s price target for the next 12 months?
Analysts predict a range of price targets between $40.00 and $60.00, with a median target of $48.90. Taking a look at these predictions, the average price target given by analysts for Royalty Pharma plc (RPRX) stock is $48.35.
